40
Participants
Start Date
June 17, 2021
Primary Completion Date
June 7, 2022
Study Completion Date
June 7, 2022
Insulin, Regular, Human
The spray will last a few seconds and then the participant will be asked to sniff to aid the drug into the nose. The device (i.e. ViaNase) is an atomizer that uses its patented technology that turns the liquid into a fine mist of droplets to facilitate the drug along the nose to brain pathway. Each nostril will receive this administration 2 times for a total of 40 IUs or 0.4 mL of liquid.
Placebo
The spray will last a few seconds and then the participant will be asked to sniff to aid the saline into the nose. The device (i.e. ViaNase) is an atomizer that uses its patented technology that turns the liquid into a fine mist of droplets to facilitate the drug along the nose to brain pathway. Each nostril will receive this administration 2 times for a total of 40 IUs or 0.4 mL of liquid.
Pennington Biomedical Research Center, Baton Rouge
Nutrition Obesity Research Center
OTHER
Pennington Biomedical Research Center
OTHER